Fehlbewertung von Beteiligungen führt zu verspäteten Wertminderungen

Definition

Under AASB 136 (Impairment of Assets), an asset is impaired when its carrying amount exceeds its recoverable amount, and entities must estimate recoverable amount when internal or external indicators exist, including when the carrying amount of the net assets exceeds market capitalisation or internal performance is worse than expected.[1] For investments in subsidiaries, joint ventures and associates, recognising dividends that exceed the investee’s total comprehensive income or when the investor’s carrying amount exceeds the investee’s net assets (including goodwill) are specific impairment indicators.[1] Holding companies that rely on outdated forecasts, optimistic assumptions or infrequent testing often delay impairment; Discovery Alert’s review of ASX companies notes that commodity price volatility, interest rate changes and macro shocks frequently trigger significant impairment charges that materially affect profit and equity.[5][3] These delayed write‑downs can run into tens or hundreds of millions of AUD for listed groups, signalling prior misallocation of capital and reducing market valuation multiples.

Why This Matters

The Pitch: Holding companies in Australia 🇦🇺 waste AUD 5–20 million per major investment cycle through delayed recognition of impairment and mispriced capital allocation. Automation and independent valuation of impairment testing can reduce write‑off volatility and avoid 2–5% value erosion on under‑performing investments.

Affected Stakeholders

Group CFO, Head of Group Reporting, Investment Committee members, Board Audit & Risk Committee, External auditors, Valuation specialists

Related Business Risks